E
ATRS

Ergoteles’s Antares Pharma, Inc. ATRS Stock Holding History

Ergoteles’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,600
Closed -$107K – 1840
2021
Q2 		$107K Buy
+24,600
New +$100K ﹤0.01% 1400
2020
Q4 		– Sell
-17,400
Closed -$47K – 983
2020
Q3 		$47K Buy
+17,400
New +$48.2K 0.01% 557

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Ergoteles's ATRS Position: Q3 2021 in Review

Ergoteles sold out of Antares Pharma, Inc. (ATRS) in Q3 2021, closing a stake of 24,600 shares — an estimated $107K sold.

Ergoteles first reported a position in ATRS in Q3 2020 and held it in 2 quarters. The position peaked at $107K in Q2 2021. 170 funds tracked by Wall St. Rank hold ATRS as of Q3 2021.

  • Ergoteles reported no remaining Antares Pharma, Inc. position as of Q3 2021 after selling out during the quarter.
  • Ergoteles sold 24,600 Antares Pharma, Inc. shares in Q3 2021, an estimated $107K.
  • Ergoteles first reported a position in Antares Pharma, Inc. in Q3 2020 and held it in 2 quarters.
  • Ergoteles's Antares Pharma, Inc. position peaked at $107K in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.